Viewing nowDiosartan 160 mg (Valsartan)
Valsartan 160mg
Tablet · Prescription medication
Yuhan Corporation

MFDS item code 200811104 · Notified 2008.11.20 · Insurance code 642104020
Treatment of essential hypertension and heart failure; reduces the risk of death after myocardial infarction
This medication is used to treat essential hypertension. It is also effective for heart failure patients who cannot use ACE inhibitors, especially those classified as NYHA class II to IV. After myocardial infarction, it helps reduce the risk of death in stable patients with left ventricular dysfunction or left ventricular systolic dysfunction. Hence, it plays a significant role not only in controlling hypertension and managing heart failure but also in improving survival rates after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, it is recommended that the medicine be taken at the same time each day (e.g., in the morning). Adults: Regardless of sex or race, the recommended dose is 80 mg of valsartan orally once daily. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be coadministered. If further blood pressure reduction is needed, the dose may be increased to a maximum of 320 mg daily. Older adults (75 years and older): Start treatment with 40 mg of this medicine once daily. Patients with renal impairment: Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; the dose should not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily; the dose may be increased to 80 mg or 160 mg per dose. When coadministering a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, administered in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours after the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily, followed by dose increases over several weeks, as tolerated by the patient, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for patients with a creatinine clearance of 10 mL/min or higher; however, do not administer this medicine to patients with a creatinine clearance less than 10 mL/min or to patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: For patients with mild or moderate hepatic impairment, the daily dose of this medicine should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
Safety and efficacy have not been established in children and adolescents under 18 years of age. Safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus if taken during pregnancy, especially in the second and third trimesters, so it should be stopped immediately upon confirmation of pregnancy. Women who are pregnant or breastfeeding, and people allergic to this drug or its components, should not take it. It is also not safe for patients severely impaired in liver or kidney function, or with a history of angioedema. Elderly patients, those with hyperkalemia, mildly impaired liver function, and those with cardiovascular diseases should use this medication cautiously, starting at a lower dose and monitoring their condition closely. This drug lowers blood pressure and may cause a rapid drop in blood pressure when first taken; if symptoms like dizziness or fainting occur, consult a doctor immediately. During treatment, it's important to regularly monitor blood pressure, as well as kidney function and blood potassium levels. When taken concurrently with other antihypertensives, diuretics, potassium-sparing diuretics, and some anti-inflammatory pain relievers, interactions may occur, so be sure to inform a physician or pharmacist. Caution is required when driving or operating machinery due to the possibility of dizziness. In case of an overdose, symptoms like hypotension or altered consciousness may occur, requiring prompt medical attention. Safety for children and adolescents has not been established; therefore, it's advised not to use this medication in these populations. This drug should be kept out of reach of children and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication is sensitive to air and moisture and should be stored in a tightly closed container. Additionally, it is important to store it in a cool place, below 30 degrees Celsius, to maintain its efficacy.
Oval film-coated tablet with a grayish-orange color
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 160mg
Tablet · Prescription medication
Yuhan Corporation

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.